<DOC>
	<DOCNO>NCT03012594</DOCNO>
	<brief_summary>This human research study look effectiveness Lanreotide ( study medication ) treat small bowel motility disorder . It similar natural hormone somatostatin produce body stomach , duodenum , pancreas brain . Somatostatin growth hormone-inhibiting hormone . Lanreotide man make hormone long act medication give month . It market trade name `` Somatuline Depot '' . It give deep subcutaneously ( deep within layer skin ) superior external quadrant buttock . Injection site alternate subsequent injection .</brief_summary>
	<brief_title>Lanreotide Treatment Small Bowel Motility Disorders</brief_title>
	<detailed_description>The investigator hypothesize patient small bowel motility disorder , Lanreotide help alleviate symptom . Lanreotide FDA approve medication management acromegaly neuroendocrine tumor , never use treat small bowel motility disorder . However , Octreotide similar Lanreotide short act synthetic somatostatin use research study . If patient interested qualifies study he/she explain study signature collect consent form . Health social history collect . Blood work , urine analysis , pregnancy test ( woman reproductive age group capability get pregnant ) ) perform make sure patient qualifies study follow-up treatment . Physical examination , ECG , wireless motility capsule test hydrogen breath test perform . Patients require complete questionnaire regard health . The total study duration first administration study drug 12 week . The study medication give month 3 month 1 month follow-up last study medication . There screen visit approximately 1 month first study drug administration .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>1 . Consecutive patient evidence small bowel motility disorder , refer ( ) patient Gastroenterology Motility Center Northwell Health System . 2 . Aged 18 70 year . 3 . Subjects capable understand study able give inform consent . 4 . Patient small bowel motility disorder evidence delay small bowel transit wireless motility capsule ( WMC ) test &gt; 6 hour . 5 . To participate study , patient stop take Octreotide ( mechanism action study medication ) theyare currently take ; stop least 4 week take first dose study medication . General Exclusion Criteria 1 . Age &lt; 18 age &gt; 70 2 . Pregnancy assess urine pregnancy test . Exclusion Criteria perform wireless motility capsule test 1 . History gastric bezoar 2 . History Disorders swallow 3 . Known suspect small bowel diverticulum , diverticulitis , stricture , fistula , Crohn 's disease , relevant medical comorbidity ( e.g . chronic alcohol abuse ) 4 . Prior intestinal surgery , include IC valve resection gastrointestinal surgery create blind loop ( e.g . Bilroth II RouxenY ) 5 . History Severe dysphagia food pill 6 . A participant us implant portable electromechanical medical device cardiac pacemaker infusion pump 7 . Inability intestinal transit alter medication least one week ( e.g . opiate , laxative , etc . ) 8 . Any person unable unwilling undergo abdominal surgery . 9 . BMI &gt; 40 . Exclusion Criteria due Lanreotide 1 . Current use recent ( within last 7 day ) use acid suppressive therapy , prokinetic agent , laxative , opiate , agent know affect gastrointestinal motility . 2 . Disorders associate presumed small intestinal motility disorder include : scleroderma , intestinal pseudoobstruction , autonomic visceral neuropathy ( e.g . longstanding diabetes 20 year and/or poorly control diabetes ( glucose &gt; 250 , glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % ) 3 . Current use cyclosporine ( Gengraf , Neoral , Sandimmune ) , medicine call bromocriptine ( Parlodel , Cycloset ) , medicine low heart rate , beta blocker . 4 . Cardiac arrhythmia base health history ( palpitation , feel pause heartbeat , lightheadedness , passing , shortness breath , chest pain ) . Bradycardia Tachycardia monitor every visit clinic , use pulse rate . ECG perform screen visit 8th week study . The follow accessed ECG . Bradycardia &lt; 60 beats/min . Tachycardia &gt; 100 beats/min . Atrial Fibrillation Rapid irregular atrial signal real Pwaves irregular ventricular rate . Ventricular Fibrillation Irregular ventricular waveform . Sinus Arrhythmia Normal beat , trigger irregular interval 60 100 BPM , cause vary RR interval . Missed beat . 5 . Chronic kidney disease ( moderate severe renal impairment calculate creatinine clearance &lt; 50 mL/min ) 6 . Hepatic Impairment Subjects ChildPugh Class B Class C. 7 . Significant electrolyte abnormality : Anything outside normal range +/ 20 % consider abnormal . 8 . Cholilithiasis ( Total bilirubin &gt; 2x normal ) 9 . Pancreatitis 10 . Hepatitis ( AST , ALT Alk Ph , great upper limit normal ( ULN ) , Serum albumin &lt; 3.0 g/dL unless prothrombin time within normal range ) 11 . Present cholecystitis 12 . Uncontrolled congestive heart failure 13 . Known hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Small bowel motility disorder</keyword>
	<keyword>Slow intestinal motility</keyword>
	<keyword>Small bowel bacterial overgrowth</keyword>
</DOC>